OLMA Olema Pharmaceuticals, Inc.
Nasdaq · SEC CIK 1750284 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $24.74M 11 sales by 6 insiders
- Filings on record
- 177 since 2021-07-13, latest 2026-09-02 16:30
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| CLARK IAN T | Dir | — | $7.87M |
| Zojwalla Naseem | Chief Medical Off | — | $7.53M |
| Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | — | $4.66M |
| Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | — | $2.98M |
| Mitchell Shawnte | CLO | — | $951.5K |
| Harmon Cyrus | Dir | — | $743.8K |
| Austin Sasha Lu | VP of Fin, Ctrl | — | — |
| Bohen Sean | Pres, CEO, Dir | — | — |
| RAPPAPORT ANDREW | Dir | — | — |
Transactions 128
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-07-27 19:30 | 2026-07-23+ | OLMA | Harmon Cyrus | Dir | S - Sale | $11.65 | -25.0K | 702.8K | -3% | -$291.2K |
| DM | 2026-03-05 | 2026-03-03+ | OLMA | Mitchell Shawnte | CLO | S - Sale+OE | $23.79 | -40.0K | 233 | -99% | -$951.5K |
| DM | 2026-03-05 | 2026-03-03+ | OLMA | Mitchell Shawnte | CLO | M - OptEx | $4.37 | +40.0K | 15.0K | New | +$174.8K |
| D | 2026-02-17 | 2026-02-02 | OLMA | Austin Sasha Lu | VP of Fin, Ctrl | A - Grant | $0.00 | +11.7K | 16.2K | +261% | $0 |
| 2026-01-21 | 2026-01-20 | OLMA | Harmon Cyrus | Dir | S - Sale | $26.88 | -10.0K | 727.8K | -1% | -$268.8K | |
| 2026-01-16 | 2026-01-14 | OLMA | Harmon Cyrus | Dir | S - Sale | $29.12 | -3,489 | 737.8K | -0.5% | -$101.6K | |
| M | 2026-01-15 | 2026-01-13+ | OLMA | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | S - Sale | $28.70 | -103.8K | 139.7K | -43% | -$2.98M |
| DI | 2026-01-14 | 2026-01-12 | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale+OE | $28.34 | -10.0K | 144.8K | -6% | -$283.4K |
| DM | 2026-01-14 | 2026-01-13+ | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | M - OptEx | $4.87 | +100.0K | 592.8K | +20% | +$487.0K |
| DM | 2026-01-14 | 2026-01-13+ | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale+OE | $28.24 | -100.0K | 542.8K | -16% | -$2.82M |
| 2025-12-30 | 2025-12-26 | OLMA | Bohen Sean | Pres, CEO, Dir | G - Gift | $0.00 | -8,500 | 237.7K | -3% | $0 | |
| 2025-12-29 | 2025-12-22 | OLMA | Harmon Cyrus | Dir | S - Sale | $28.53 | -2,881 | 741.3K | -0.4% | -$82.2K | |
| DM | 2025-12-23 | 2025-12-19+ | OLMA | Zojwalla Naseem | Chief Medical Off | S - Sale+OE | $27.94 | -269.5K | 4,488 | -98% | -$7.53M |
| DM | 2025-12-23 | 2025-12-19+ | OLMA | Zojwalla Naseem | Chief Medical Off | M - OptEx | $11.89 | +140.0K | 154.0K | +1,000% | +$1.66M |
| 2025-12-23 | 2025-12-19 | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | G - Gift | $0.00 | -9,000 | 542.9K | -2% | $0 | |
| M | 2025-12-23 | 2025-12-19 | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale | $30.46 | -51.0K | 601.7K | -8% | -$1.55M |
| DM | 2025-12-23 | 2025-12-19 | OLMA | CLARK IAN T | Dir | M - OptEx | $4.61 | +264.8K | 264.8K | New | +$1.22M |
| DM | 2025-12-23 | 2025-12-19 | OLMA | CLARK IAN T | Dir | S - Sale+OE | $29.73 | -264.8K | 0 | -100% | -$7.87M |
| 2025-12-09 | 2025-12-08 | OLMA | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | G - Gift | $0.00 | -75.0K | 243.5K | -24% | $0 | |
| 2025-12-01 | 2025-11-26 | OLMA | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | G - Gift | $0.00 | -225.0K | 318.5K | -41% | $0 | |
| D | 2025-11-25 | 2025-11-21 | OLMA | RAPPAPORT ANDREW | Dir | M - OptEx | $0.39 | +35.9K | 35.9K | New | +$14.0K |
| D | 2025-11-25 | 2025-11-25 | OLMA | RAPPAPORT ANDREW | Dir | G - Gift | $0.00 | -35.9K | 0 | -100% | $0 |
| M | 2025-09-18 | 2025-09-16+ | OLMA | Harmon Cyrus | Dir | S - Sale | $8.19 | -20.0K | 744.1K | -3% | -$163.7K |
| MI | 2025-09-18 | 2025-09-16+ | OLMA | Harmon Cyrus | Dir | S - Sale | $8.23 | -5,000 | 120.1K | -4% | -$41.1K |
| DM | 2025-01-14 | 2025-01-10 | OLMA | BVF Partners OS Ltd. | Dir, See Explanation of Responses | D - Sale to Iss | — | -420.0K | 348.0K | -55% | — |
| DI | 2025-01-13 | 2025-01-08 | OLMA | Bain Capital Life Sciences Investors, LLC | 10% | P - Purchase | $5.76 | +300.0K | 7.80M | +4% | +$1.73M |
| DI | 2025-01-13 | 2025-01-10 | OLMA | Bain Capital Life Sciences Investors, LLC | 10% | J - Other | — | -3.50M | 4.30M | -45% | — |
| AI | 2024-12-18 | 2024-12-13 | OLMA | Graham G. Walmsley | Dir | S - Sale | $6.75 | -700.8K | 0 | -100% | -$4.73M |
| AI | 2024-12-18 | 2024-12-13 | OLMA | Graham G. Walmsley | Dir | P - Purchase | $6.75 | +700.8K | 700.8K | New | +$4.73M |
| D | 2024-12-17 | 2024-12-16 | OLMA | Zojwalla Naseem | Chief MEDICAL Off | M - OptEx | $4.87 | +14.0K | 129.5K | +12% | +$68.2K |
| I | 2024-12-17 | 2024-12-17 | OLMA | Graham G. Walmsley | Dir | P - Purchase | $6.75 | -700.8K | 1.41M | -33% | -$4.73M |
| I | 2024-12-17 | 2024-12-17 | OLMA | Graham G. Walmsley | Dir | S - Sale | $6.75 | -700.8K | 0 | -100% | -$4.73M |
| 2024-12-11 | 2024-12-09 | OLMA | Harmon Cyrus | Dir | A - Grant | $0.00 | +29.2K | 780.5K | +4% | $0 | |
| M | 2024-12-11 | 2024-12-10+ | OLMA | Harmon Cyrus | Dir | S - Sale | $9.03 | -16.4K | 764.1K | -2% | -$148.0K |
| M | 2024-12-11 | 2024-12-10+ | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale | $9.01 | -26.1K | 611.9K | -4% | -$234.9K |
| 2024-12-11 | 2024-12-09 | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | A - Grant | $0.00 | +48.8K | 624.4K | +8% | $0 | |
| 2024-12-11 | 2024-12-09 | OLMA | Zojwalla Naseem | Chief MEDICAL Off | A - Grant | $0.00 | +52.0K | 143.3K | +57% | $0 | |
| M | 2024-12-11 | 2024-12-10+ | OLMA | Zojwalla Naseem | Chief MEDICAL Off | S - Sale | $9.01 | -27.8K | 130.0K | -18% | -$250.5K |
| 2024-12-11 | 2024-12-09 | OLMA | Bohen Sean | Pres AND CEO, Dir | A - Grant | $0.00 | +204.8K | 351.2K | +140% | $0 | |
| M | 2024-12-11 | 2024-12-10+ | OLMA | Bohen Sean | Pres AND CEO, Dir | S - Sale | $9.01 | -109.5K | 298.8K | -27% | -$986.4K |
| M | 2024-12-11 | 2024-12-10+ | OLMA | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | S - Sale | $9.01 | -35.2K | 543.5K | -6% | -$316.7K |
| 2024-12-11 | 2024-12-09 | OLMA | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | A - Grant | $0.00 | +68.2K | 578.7K | +13% | $0 | |
| DM | 2024-12-04 | 2024-12-04 | OLMA | BVF INC/IL | Dir, See Explanation of Responses | D - Sale to Iss | — | -3.37M | 370.7K | -90% | — |
| MAI | 2024-11-26 | 2024-06-04 | OLMA | Graham G. Walmsley | Dir | S - Sale | $14.85 | -1.18M | 700.8K | -63% | -$17.45M |
| D | 2024-11-18 | 2024-11-15 | OLMA | Kovacs Shane William Charles | Ch. Operating, Financial Off | M - OptEx | $7.02 | +25.0K | 510.5K | +5% | +$175.5K |
| MI | 2024-08-05 | 2024-08-01 | OLMA | Paradigm Biocapital Advisors LP | 10% | S - Sale | $14.92 | -2.40M | 4.72M | -34% | -$35.81M |
| M | 2024-07-31 | 2024-07-29+ | OLMA | Harmon Cyrus | Dir | S - Sale | $15.57 | -5,000 | 751.3K | -0.7% | -$77.9K |
| 2024-07-12 | 2024-07-11 | OLMA | Harmon Cyrus | Dir | S - Sale | $12.26 | -5,000 | 756.3K | -0.7% | -$61.3K | |
| 2024-07-02 | 2024-06-28 | OLMA | Harmon Cyrus | Dir | S - Sale | $10.77 | -20.0K | 761.3K | -3% | -$215.4K | |
| MI | 2024-06-06 | 2024-06-04 | OLMA | Graham G. Walmsley | Dir | S - Sale | $14.85 | -1.18M | 700.8K | -63% | -$17.45M |
| M | 2024-06-04 | 2024-05-31+ | OLMA | Harmon Cyrus | Dir | S - Sale | $10.30 | -25.0K | 786.3K | -3% | -$257.4K |
| D | 2024-05-28 | 2024-05-24 | OLMA | Zojwalla Naseem | Chief MEDICAL Off | M - OptEx | $4.87 | +9,460 | 89.8K | +12% | +$46.1K |
| 2024-05-07 | 2024-05-06 | OLMA | Harmon Cyrus | Dir | S - Sale | $10.92 | -5,000 | 806.3K | -0.6% | -$54.6K | |
| 2024-05-02 | 2024-04-30 | OLMA | Harmon Cyrus | Dir | S - Sale | $9.51 | -15.0K | 811.3K | -2% | -$142.7K | |
| 2024-03-29 | 2024-03-28 | OLMA | Harmon Cyrus | Dir | S - Sale | $10.97 | -20.0K | 826.3K | -2% | -$219.4K | |
| D | 2024-03-20 | 2024-03-18 | OLMA | Zojwalla Naseem | Chief MEDICAL Off | M - OptEx | $4.87 | +13.7K | 80.4K | +21% | +$66.7K |
| MI | 2024-03-06 | 2024-03-05 | OLMA | RAPPAPORT ANDREW | Dir | J - Other | $0.00 | -95.0K | 0 | -100% | $0 |
| M | 2024-03-04 | 2024-02-29 | OLMA | Harmon Cyrus | Dir | S - Sale | $12.41 | -25.0K | 846.3K | -3% | -$310.3K |
| M | 2024-02-02 | 2024-01-31+ | OLMA | Harmon Cyrus | Dir | S - Sale | $12.79 | -30.0K | 871.3K | -3% | -$383.6K |
| D | 2024-01-29 | 2024-01-25 | OLMA | Zojwalla Naseem | Chief MEDICAL Off | M - OptEx | $7.02 | +20.0K | 66.7K | +43% | +$140.4K |
| D | 2024-01-16 | 2024-01-12 | OLMA | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | M - OptEx | $7.02 | +50.0K | 485.0K | +11% | +$351.0K |
| M | 2024-01-02 | 2023-12-29 | OLMA | Harmon Cyrus | Dir | S - Sale | $13.38 | -25.0K | 903.8K | -3% | -$334.5K |
| MI | 2023-12-18 | 2023-09-12+ | OLMA | Graham G. Walmsley | Dir | P - Purchase | $10.74 | +640.0K | 1.67M | +62% | +$6.87M |
| D | 2023-12-12 | 2023-12-11 | OLMA | Zojwalla Naseem | Chief MEDICAL Off | M - OptEx | $7.02 | +2,900 | 46.7K | +7% | +$20.4K |
| D | 2023-12-12 | 2023-12-12 | OLMA | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | M - OptEx | $7.02 | +10.0K | 435.0K | +2% | +$70.2K |
| I | 2023-12-08 | 2023-12-06 | OLMA | Paradigm BioCapital International Fund Ltd. | 10% | P - Purchase | $11.60 | +100.0K | 6.59M | +2% | +$1.16M |
| D | 2023-12-07 | 2023-12-06 | OLMA | Zojwalla Naseem | Chief MEDICAL Off | M - OptEx | $7.02 | +13.1K | 43.8K | +43% | +$92.0K |
| 2023-12-01 | 2023-11-30 | OLMA | Harmon Cyrus | Dir | S - Sale | $12.57 | -25.0K | 926.3K | -3% | -$314.2K | |
| M | 2023-11-22 | 2023-11-21+ | OLMA | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | S - Sale | $14.39 | -18.7K | 434.8K | -4% | -$269.7K |
| 2023-11-22 | 2023-11-20 | OLMA | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | A - Grant | $0.00 | +36.8K | 443.7K | +9% | $0 | |
| M | 2023-11-22 | 2023-11-21+ | OLMA | Bohen Sean | Pres AND CEO, Dir | S - Sale | $14.40 | -57.2K | 172.9K | -25% | -$824.1K |
| 2023-11-22 | 2023-11-20 | OLMA | Bohen Sean | Pres AND CEO, Dir | A - Grant | $0.00 | +110.2K | 202.2K | +120% | $0 | |
| 2023-11-22 | 2023-11-20 | OLMA | Zojwalla Naseem | Chief MEDICAL Off | A - Grant | $0.00 | +28.0K | 45.2K | +163% | $0 | |
| M | 2023-11-22 | 2023-11-21+ | OLMA | Zojwalla Naseem | Chief MEDICAL Off | S - Sale | $14.38 | -14.6K | 30.7K | -32% | -$209.3K |
| 2023-11-22 | 2023-11-20 | OLMA | Harmon Cyrus | Dir | A - Grant | $0.00 | +15.8K | 959.5K | +2% | $0 | |
| M | 2023-11-22 | 2023-11-21+ | OLMA | Harmon Cyrus | Dir | S - Sale | $14.39 | -8,181 | 951.3K | -0.9% | -$117.7K |
| M | 2023-11-22 | 2023-11-21+ | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale | $14.40 | -13.6K | 574.1K | -2% | -$196.2K |
| 2023-11-22 | 2023-11-20 | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | A - Grant | $0.00 | +26.2K | 587.7K | +5% | $0 | |
| 2023-11-13 | 2023-11-08 | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale | $17.61 | -200 | 561.3K | -0.0% | -$3,522 | |
| M | 2023-11-03 | 2023-11-01+ | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale | $15.26 | -10.5K | 561.5K | -2% | -$160.8K |
| M | 2023-11-02 | 2023-10-31+ | OLMA | Harmon Cyrus | Dir | S - Sale | $12.65 | -30.0K | 943.7K | -3% | -$379.4K |
| 2023-10-03 | 2023-09-29 | OLMA | Harmon Cyrus | Dir | S - Sale | $12.41 | -25.0K | 973.7K | -3% | -$310.2K | |
| 2023-09-21 | 2023-09-19 | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale | $12.67 | -20.0K | 572.0K | -3% | -$253.4K | |
| M | 2023-09-14 | 2023-09-12 | OLMA | Biotechnology Value Trading Fund OS LP | Dir, See Explanation of Responses | P - Purchase | $9.84 | +1.51M | 3.58M | +72% | +$14.82M |
| I | 2023-09-14 | 2023-09-14 | OLMA | Biotechnology Value Trading Fund OS LP | Dir, See Explanation of Responses | J - Other | — | +99.6K | 99.6K | New | — |
| A | 2023-09-05 | 2023-08-16 | OLMA | Harmon Cyrus | Dir | S - Sale | $10.14 | -15.0K | 1.02M | -1% | -$152.1K |
| M | 2023-09-05 | 2023-08-31+ | OLMA | Harmon Cyrus | Dir | S - Sale | $10.26 | -25.0K | 998.7K | -2% | -$256.6K |
| 2023-08-17 | 2023-08-16 | OLMA | Harmon Cyrus | Dir | S - Sale | $10.14 | -15.0K | 1.02M | -1% | -$152.1K | |
| 2023-06-09 | 2023-06-08 | OLMA | Harmon Cyrus | Dir | S - Sale | $6.30 | -10.0K | 1.04M | -1.0% | -$63.0K | |
| M | 2023-06-07 | 2023-06-05+ | OLMA | Harmon Cyrus | Dir | S - Sale | $6.17 | -10.0K | 1.05M | -0.9% | -$61.8K |
| 2023-04-07 | 2023-04-06 | OLMA | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | P - Purchase | — | +10.0K | 396.2K | +3% | — | |
| A | 2022-09-23 | 2022-09-21 | OLMA | Bohen Sean | Pres AND CEO, Dir | P - Purchase | — | +20.0K | 74.3K | +37% | — |
| 2022-09-22 | 2022-09-21 | OLMA | Bohen Sean | Pres AND CEO, Dir | A - Grant | — | +20.0K | 74.3K | +37% | — | |
| 2022-09-06 | 2022-09-02 | OLMA | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | P - Purchase | — | +20.0K | 381.2K | +6% | — | |
| M | 2022-06-14 | 2022-06-10 | OLMA | Biotechnology Value Trading Fund OS LP | Dir, See Explanation of Responses | P - Purchase | $4.03 | +200.0K | 2.91M | +7% | +$806.0K |
| D | 2022-03-14 | 2022-03-10 | OLMA | Horn Kinney | Chief BUSINESS Off | M - OptEx | $2.06 | +5,253 | 7,711 | +214% | +$10.8K |
| D | 2022-03-14 | 2022-03-10 | OLMA | Horn Kinney | Chief BUSINESS Off | S - Sale+OE | $4.75 | -5,253 | 2,458 | -68% | -$25.0K |
| D | 2022-02-14 | 2022-02-10 | OLMA | Horn Kinney | Chief BUSINESS Off | M - OptEx | $2.06 | +5,251 | 7,709 | +214% | +$10.8K |
| D | 2022-02-14 | 2022-02-10 | OLMA | Horn Kinney | Chief BUSINESS Off | D - Sale to Iss | — | -5,251 | 2,458 | -68% | — |
| D | 2022-01-11 | 2022-01-10 | OLMA | Horn Kinney | Chief BUSINESS Off | M - OptEx | $2.06 | +5,251 | 7,709 | +214% | +$10.8K |
Purchase Sale Sale after option exercise All abbreviations